HIK vs. HCM, INDV, AMYT, AGY, APH, ANCR, VLG, DNL, EAH, and STX
Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Hikma Pharmaceuticals vs. Its Competitors
Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.
Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.
In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than HUTCHMED. MarketBeat recorded 3 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.34 beat HUTCHMED's score of -0.02 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.
42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 39.0% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Hikma Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
Hikma Pharmaceuticals presently has a consensus target price of GBX 2,560, indicating a potential upside of 29.23%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.
Summary
Hikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks.
Get Hikma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hikma Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:HIK) was last updated on 7/2/2025 by MarketBeat.com Staff
Free HIK Stock Alerts